Recent Advances in Elastic Liposomes: Current Status and Future Perspective

Ravika Nanda¹, Raman Deep Singh Narang², Anmoldeep Kaur¹, Mehak¹, Karanbir¹ and Jasjeet Kaur Narang¹*

¹Department of Pharmaceutics, Khalsa College of Pharmacy, Amritsar, India.
²Department of Oral and Maxillofacial Pathology, Sri Guru Ram Das Institute of Dental Sciences and Research, Amritsar, Punjab, India.

Authors’ contributions

This work was carried out in collaboration among all authors. Authors RN and JKN designed the study, performed the statistical analysis, wrote the protocol and wrote the first draft of the manuscript. Author RDSN managed the analyses of the study. Authors AK, Mehak and Karanbir managed the literature searches. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i31A31664
Editor(s):
(1) Dr. Mohamed Fawzy Ramadan Hassanien, Zagazig University, Egypt.
(2) Muhammad Asim Farooq, Monash Institute of Pharmaceutical Sciences, Monash University, Australia.
(3) Shanta Kumari Adiki, Sarojini Naidu Vanita Pharmacy Maha Vidyalaya, India.
(4) V. Anu, KVM College of Pharmacy, India.

Complete Peer review History: http://www.sdiarticle4.com/review-history/68915

Received 22 March 2021
Accepted 29 May 2021
Published 08 June 2021

ABSTRACT

Elastic liposomes (ELs) are the flexible liposomes formulated using phospholipids as well as edge activators. Edge activators provide elasticity to the ELs. ELs provide advantages over other formulations and have the ability to be delivered by different routes such as topical, transdermal, nasal, ocular, etc. Potential of encapsulating not only lipophillic but also hydrophillic drugs in a single vesicle, ability to pass through channels 1/10th of their diameter, increase in drug permeation, enhanced solubility of drug, patient compliance, prevention of degradation of drug makes them efficient carriers of drugs and leads to increased interest of researchers in them. This review provides understanding of composition of ELs, advantages, method of preparation and the adaptable role played by ELs in the administration of numerous drugs for different diseases.

Keywords: ELs; advantages; composition; drug delivery.

*Corresponding author: E-mail: jasjeet2975@yahoo.com;
1. INTRODUCTION

Topical dosage form is a confined formulation, through which the drug can be administered anywhere in the body. Topical drug administration provides significant advantages over conventional systems, which include: direct availability of the drugs to the target sites, prevention of non compliance of patient due to painless administration, increased efficacy and tolerability, prevention of systemic toxicity, reduced fluctuations of drug in plasma, local delivery of drug which is also site-specific, avoidance of the first metabolism, and non intrusive administration [1].

Among the different carriers investigated for the topical delivery of drugs, ELs have been extensively investigated over the past few years due to their inherent advantages as compared to other vesicular carriers. ELs, commonly known as transferosomes, are biologically compatible double layered vesicular systems [2]. They comprise of phospholipids, surfactants which acts as edge activator (EA), and an interior hydrous cavity surrounded by double layer of lipid. Furthermore, substances like cationic lipids or anionic lipids, polyethylene glycol (PEG), cyclodextrin complexes, ethanol as well as gelling agents can be used. Its constitution affect’s its physiochemical characteristics and afterwards, potency by changing skin invasion behaviour [3].

ELs are colloidal lipid based nano sized carriers made up of special constituents with predictable ultra deformability and flexibility which help them to compress through microlamellar spaces (which have a size of $10^{-3}$ diameter of vesicle) between keratinocytes to travel undamaged beyond the layers of skin and enhance wetting of the skin to boost transepidermal water loss (TEWL) [4]. Owing to combined effect of ELs acting as a transporter and penetrant, there is increase in permeability of ELs. Magnificently EL can invade the skin without breaking or getting damaged [5].

They are known by other names such as ultra deformable liposomes, ultra flexible liposomes, transferosomes, etc. ELs have been prepared for nasal, topical, transdermal delivery and for delivery of biologics (vaccines and toxoids) dosage forms. Owing to their improved physiochemical and pharmacokinetic characteristics, ELs can overcome the problems associated with traditional drug delivery vehicles [2].

2. COMPOSITION OF ELs

Major components of ELs are amphiphilic phospholipids with several/ numerous chemical structures, edge activator (such as sodium cholate, sodium deoxycholate, span, tween and dipotassium glycyrrhizinate) [6], and aqueous compartments [Fig. 1]. By altering the type and concentration of each constituent, drug delivery from the system can be regulated [7].

![Fig. 1. Composition of ELs](image-url)
2.1 Edge Activators

Edge activator lowers the transition temperature of lipid and upsets the double layer of lipid of ELs which increases the fluidity and enhances the permeation behaviour of ELs across the skin [8].

Several properties of edge activators that should be kept in mind before manufacturing EL are given in Fig. 2.

2.2 Phospholipids

Unsaturated soya phosphatidylcholine (PC) and egg phosphatidylcholine (~10% w/w) are the most preferred phospholipids. Normally lipids have elevated transition temperature. At high temperatures, lipids are in a state of liquid crystal which results in leakage of drug (owing to enhanced permeability of confined therapeutic agent) at room temperature (25º C) and when administered to the skin (32º C). Storage stability can be prolonged by regulating the lipid double layer structure by setting its transition temperature between these temperatures [8].

Amphiphilic particles contain a glycerol bridge that forms a link between a pair of lipophilic acyl hydrocarbon chains and a hydrophilic head, which affects the lipid membrane phase transition for increased flexibility [17]. Fig. 3 contains summary of properties of lipids and their significant roles [17,18-20]. Transportation of several challenging particles at elevated concentrations within and across the layers of skin by topical delivery is enabled by such systems.

For better elasticity and stability of ELs, the proportion of lipid to edge activator should be optimal, which helps in achieving long term storage stability and an efficient permeation potential, respectively. Constituents that can be used as carriers for vesicle formulation could be cationic lipids, PEGylated lipids, gels and complexing agents that encapsulate the drug. The complexing agents include cyclodextrin and ethyl alcohol (10% of aqueous volume) [17]. Fig. 4 illustrates the composition of an elastic liposome.

![Fig. 2. Properties of edge activator affecting characteristics of ELs](image-url)
Fig. 3. Characteristics of phospholipids

Unsaturated phosphatidylycholine with a low transition temperature are mainly used for preparing ELs. Increased elastic and enhanced transdermal flux was shown by dorsolateral prefrontal cortex (DLPC) (C: 12) based ELs of sumatriptan as compared to DOPC (C: 18) composed vesicles [18].

The permeation behaviour of vesicles is affected by the purity of phosphatidylycholine. When the permeation behaviour of vesicles was studied with different purity concentrations, the finest result was acquired with 95% phosphatidylycholine [19].

The enhanced permeability of the encapsulated drug can be attributed to the lipids present in a liquid crystal state at room temperature (25°C). By altering the quantity of phosphatidylycholine in the EL bilayer, the transition temperature can be modified to set between the temperature at which they are stored and skin temperature (32°C). Furthermore, when applied to the skin, because of the temperature of the skin (32°C) being significant than its Tm, the state of vesicles turns into liquid, which eventually provides more elasticity [17].

Fig. 4. The composition of an elastic liposome

2.3 Mechanism of Permeation of ELs through the Skin

Skin acts as a prominent barrier for many drugs after their administration through topical route. When suspension of ELs is applied topically, it interacts with the skin and results in the occurrence of many sequential events [17]. Initially, the concentration of non-volatile adjunct material increases on the skin due to immediate evaporation of water present in the suspension. After reaching the saturation level, the hydration gradient down the skin to elastic liposome vesicles are well maintained. Consequently, in
the upper layer, there is increase in water content (10%-30%) in comparison to the internal living epidermis (75%) [21]. Transepidermal hydration gradients develop due to difference in water content in upper and lower layer. The vesicles are pulled towards the inner layer of the skin by water affinity of the vesicles, transepidermal hydration gradient, and high elasticity, until they have extended to the living epidermis rich in water. After liposomal vesicles have crossed the SC barrier by diffusion-mediated mechanism, the “pull” mechanism is substituted with a “push” mechanism on the vesicles. In living skin, the intracellular fluid motion may also be effectual. It is interesting that ELs cannot penetrate the SC layer without a transepidermal hydration gradient. Furthermore, the hydration gradient may be decreased when ELs are applied occlusively and therefore should not be applied occlusively [21].

2.4 Advantages OF ELs

ELs have a number of advantages over other dosage forms. The advantages are compiled in Fig. 5.

2.5 Preparation of ELs

Conventional rotary evaporation method is used for preparing the ELs [22,23]. Using different proportions of surfactants, phospholipid and potent drug, several batches of ELs are developed.

The various steps involved in the formulation of ELs are given in Fig. 6.

2.6 Characterization of Prepared ELS

2.6.1 Polydispersity index, vesicle size and zeta potential

Zetasizer is used for determining polydispersity index, vesicle size and zeta potential. After diluting each liposomal sample 30 times with HPLC Grade water, all the measurements are performed at 25°C, a scattering angle of 90°, and a laser wavelength of 633 nm. In order to figure out the values as a mean ± standard deviation, all the measurements are repeated three times [24].

2.6.2 Percentage yield of ELs

For determining the %age yield of ELs, the developed ELs are weighed and the measured weight is divided by the total weight of drug and components utilized for the development of ELs [25].

\[
\text{% age yield} = \frac{\text{weight of prepared ELs}}{\text{total weight of drug and excipients}} \times 100
\]

2.6.3 Drug entrapment efficiency (%EE)

The drug entrapment efficiency is determined by isolating the unentrapped drug by using minicolumn centrifugation method. The pellet obtained is disrupted using suitable solvent (such as methanol, triton X, etc.) The solution is filtered and the amount of drug is quantified spectrophotometrically. The percentage entrapment is calculated using the following formula [26]:

\[
\text{Percentage entrapment} = \frac{(\text{entrapped drug})}{(\text{Total drug added})} \times 100
\]

2.6.4 Vesicle morphology

Transmission electron microscope (TEM) is used for visualizing elastic liposomal formulations. A thin film is formed onto a grid coated with carbon after placing one drop of the sample on it. The film is negatively stained using 1% phosphotungastic acid before it gets dried on the grid. Onto the film, staining solution (one drop) is put and by using a filter paper, solution in excess is removed. Samples are observed under a TEM, after drying the grid in air [27].

2.6.5 Turbidity

Nephelometer is used for determining the turbidity of different formulations using suitable buffer as blank [27].

2.6.6 Elasticity

Elastic nature of the vesicles is measured by extruding the formulated vesicles at 2.5 bars through a polycarbonate millipore filter membrane which has 60–200 nm as the diameter of pores. After 10 minutes, the volume of the vesicle suspension is measured and the shape of vesicles and size is observed before and after the filtration. The following formula is used to measure the elasticity of the vesicle membrane:

\[
E = J^* \left(\frac{r_v}{r_p}\right)^2
\]

Where \(E\) = vesicle membrane elasticity; \(J^*\) = suspension amount, which will extrude during 10 min; \(r_v\) = size of vesicles size extrusion; and \(r_p\) = barrier pore size [28,7].
2.6.7 Viscosity

The viscosity of the prepared ELs suspension is measured using a viscometer at temperature of 25° C [29]. The process is repeated three times on each sample to get a mean value [30].

2.6.8 Spreadability

The main factor of the formulations developed for topical application that provides advantage over formulations which are non-spreading or poorly spreadable is the degree of spreading capability of the formulation. To make sure that the dosage form applied topically leaves a fine film on skin, spreadability is an important parameter to acquit [30].

Between graduated flat glass surfaces, a weighed amount (1g) of the elastic liposome suspension is kept and pressed with weights which are increased (50-500g) after different time points. The developed diameter is estimated to determine the surface area (cm²) at different time intervals. The procedure is carried out at 25° C [31].

2.6.9 In vitro drug release assessment

The test is performed in a Franz diffusion cell using a dialysis membrane, which is kept in between the donor and the recipient compartment of the diffusion cell and the sample is placed on it. The study is conducted under continuous stirring (100 rpm) using a magnetic bead and at a temperature of 37± 1° C. At
pre-determined time points, the samples are collected and the amount of sample collected is restored by adding fresh buffer. The samples collected are assessed spectrophotometrically to estimate the released drug content [32].

2.6.10 Ex vivo permeation study

The ex vivo permeation study is performed using the rat skin in a diffusion cell [33] after removal of unnecessary fatty debris and hairs. The cleaned skin is kept in between the compartments of the diffusion cell and the dosage form is applied onto the epidermal surface of the skin. The temperature is maintained at 37 ± 1°C and the release medium is continuously stirred at 50 rpm using a magnetic bead [34]. At given time intervals, the samples are withdrawn and the volume withdrawn is replaced by equal volume of fresh buffer. The amount of drug permeated is assayed spectrophotometrically [32].

2.6.11 In vivo study

For in vivo study, various animals such as rats, mice, rabbits, etc are used depending on the type of activity or testing involved in the evaluation of the formulation prepared. Table 1 shows various examples of in vivo studies carried out using Elastic liposomal formulations.

3. APPLICATIONS OF ELs IN THE TREATMENT OF DIFFERENT DISEASES

Elastic liposomes have been investigated extensively by researchers for delivery of drugs and other therapeutic agents for the effective treatment of many diseases. The common diseases for which the delivery of drugs by formulation of ELs has proven to be effective are given below:

3.1 Atopic Dermatitis

Goindi et al., 2013 formulated nanosized elastic liposome based dosage form of cetirizine dihydrochloride for topical administration using phospholipon 90 G and surfactant to target peripheral H1 antihistaminic activity. The optimization of the prepared formulation was done on the basis of phospholipid/drug/charge inducer ratio and concentration of surfactant. The optimized dosage form was satisfactory in terms of stability, content of drug, pH, entrapment efficiency, size of vesicles, viscosity, spreadability as well as morphology. The ex vivo permeation study was carried out using Franz diffusion cell and mice skin. The mean cumulative percentage of drug permeated in 8 hours was found to be approximately double (60.001±0.332) in comparison to commercially available cream (33.268±0.795) and drug solution (32.616±0.969), thereby recommending enhanced penetration as well as permeation of drug from the elastic vesicles. Additionally, oxazolone-induced atopic dermatitis in mice was used for assessing the therapeutic efficacy of optimized formulation. The developed formulation was found to be beneficial in lowering the itching score (4.75 itches per 20 min) in comparison to conventional cream (9.75 itches per 20 min) with marked decrease in count of eosinophils of dermis as well as erythema score. It was concluded that ELs were non toxic and safe for dermal application. The authors concluded that the formulated elastic liposomal formulation had potential for treating atopic dermatitis [35].

Lie and coworkers formulated tacrolimus loaded transfersomes (TFs) and evaluated their potential for treating atopic dermatitis in mice. A comparison of the formulation was done with commercial tacrolimus ointment (Protopic®) as well as liposomes-gel. Among the various carriers (sodium cholate, Tween 80 and Span 80) evaluated for the formulation of TFs, Tween 80 was chosen as the optimized carrier based on its highest deformability as well as maximum drug retentions. The optimized TFs were later converted into gel. The results of in vitro drug release of TFs-gel indicated a higher drug release after 24 h in comparison to the commercial ointment. The TFs-gel exhibited an in vitro drug release of 37.6% after 12 hours. Significantly higher drug retention in the skin was obtained for the optimized TFs-gel as compared to the liposomes-gel and ointment available commercially. The tacrolimus present in the epidermis as well as in the dermis after the application of TFs-gel was found to be 3.8 times and 4.2 times higher in comparison to the ointment. The liposomes-gel also exhibited higher levels of the drug in the epidermis and the dermis (1.7 times and 1.4 times respectively) as compared to the commercial ointment. The authors reported that the developed formulation exhibited best curative action on 2, 4-dinitrofluorobenzene induced atopic dermatitis in mice. Based on the results the authors suggested that TFs exhibited better performance as well as effective skin targeting of tacrolimus after topical application [43].
Table 1. Examples of *in vivo* studies carried out using elastic liposomal formulations

| S. No | Drug                                      | Animal used               | In vivo study                                      | Outcome                                                                                                                                                                                                 | Reference |
|-------|-------------------------------------------|---------------------------|----------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 1     | Cetirizine dihydrochloride                 | Female BALB/c mice        | Pharmacodynamic evaluation against atopic dermatitis (change in erythema score and number of itching/scratching) | Marked reduction in itching score was observed in case of cetirizine loaded ELs when compared with results of conventional cream                                                                              | [35]      |
| 2     | Cyclodextrin-Colchicine Complexes          | Rats                      | Anti gout activity                                | Better anti-gout activity was shown by the developed formulation in comparison to drug solution                                                                                            | [36]      |
| 3     | Sodium stibogluconate and ketoconazole     | Female BALB/c mice        | Anti-leishmanial studies                          | Complete removal of lesion in mice, lower parasite burden in comparison to mice treated with other formulations, thus indicating better anti-leishmanial activity                                | [37]      |
| 4     | 5-Fluorouracil                             | Mice                      | Draize study                                      | The formulation was proved to be safe and non-irritant as no erythema or inflammation was observed                                                                                                         | [7]       |
| 5     | Rifampicin                                 | Sprague Dawley rats       | Pharmacokinetic study                             | Rifampicin loaded elastic liposomes showed improved pharmacokinetic parameters as compared to oral administration                                                                                     | [30]      |
| 6     | Ciprofloxacin                              | White albino rabbits      | Pharmacokinetic analysis                          | Ciprofloxacin loaded ELs showed improved bioavailability in comparison to commercial eye drops                                                                                                         | [38]      |
| 7     | Aceclofenac                                | Male laca mice            | Analgesic effect using radiant heat tail flick method | Enhanced analgesic effect                                                                                                                                                                                                                                      | [39]      |
| 8     | Propranolol hydrochloride                  | Albino rats               | Plasma concentration studies                      | Higher plasma concentration was found in case of rats treated with propranolol loaded ELs in comparison to other formulations                                                                                                                                     | [40]      |
| 9     | Ammonium glycyrrhizate                     | Human volunteers          | Evaluation of cutaneous tolerability, anti-inflammatory activity | Increased anti-inflammatory activity after encapsulation in ELs in comparison to control and drug suspension                                                                                    | [41]      |
| 10    | Lornoxicam                                 | Rats                      | Anti-inflammatory activity using rat induced carrageenan paw edema method | Significant reduction in induced paw edema when compared with non-transferosomal gel and indomethacin gel                                                                                 | [42]      |
3.2 Hypertension

Manvir and coworkers formulated elastic vesicles of nifedipine for transdermal delivery. The vesicles containing nifedipine were developed by using rotary evaporator and different characteristics such as size, shape, size distribution, number of vesicles, entrapment efficiency, as well as stability were evaluated. Among the different formulations of Els, one formulation was optimized on the basis of entrapment efficiency for evaluation of the additional parameters. The entrapment efficiency was found to be higher in transfosromal formulation as compared to the liposomal formulation. The number of vesicles formulated transfersomes was found to be more as compared to liposomal formulation. Franz diffusion cell was utilized for carrying out the in vitro drug release study. A lower release rate of nifedipine was found from elastic vesicles in comparison to liposomes. Ex vivo study was carried out on male albino rats and the results of ex vivo study were used to compare the performance of ELs and the liposomes solution. From the skin study, it was found that the skin permeation was higher for elastic liposomal formulation (76.41±0.9) in comparison to nifedipine loaded liposomal solution (71.44±0.9). No change was observed in the consistency of transfersomal formulation and no drug crystals appeared during the stability studies. Hence, the study concluded that transfersomal formulation of nifedipine had significant capability to enhance permeation of the entrapped drug across skin and prolong release of drug besides providing site specificity [44].

Ahad and coworkers formulated and evaluated the potential of eprosartan mesylate (EM) loaded nanotransfersomes for transdermal delivery. Phospholipon 90G, sodium deoxycholate (SDC) and Span 80 (SP) were utilized for the formulation of nanovesicles. The formulation which was considered optimized exhibited 108.53 ± 0.06 nm as the size of the vesicles and 63.00 ± 2.76% as the entrapment efficiency. The authors reported that the formulated transfersomes exhibited an enhanced flux (27.22 ± 0.29 µg/cm²/h) and enhancement ratio of 16.80 as compared to the conventional liposomes when evaluated using rat skin. The results of the confocal laser microscopy confirmed that the formulated dosage form successfully permeated and distributed through deep layers of rat skin. Based on the study results the authors also inferred that nature as well as the edge activator concentration and nature of surfactants influenced the properties of transfersomes immensely. The authors confirmed that nano transfersomes were a potential drug delivery system for the delivery of EM through the rat skin [45].

3.3 Anti-Histaminic Activity

Ahayed and coworkers looked into feasible mechanisms through which transfersomes and ethosomes enhanced delivery of ketotifen under non-intrusive state in skin. Rabbit pinna skin was used for studying the in vitro permeation as well as deposition studies of transfersomes and ethosomes, possessing ketotifen both within and externally on the vesicles, possessing ketotifen only within the vesicles and possessing ketotifen only on the outside of the vesicles. The authors proposed that the penetration increasing impact as the permeation of intact vesicle into the stratum corneum could enhance delivery of drugs in the skin by transfersomes, under non-intrusive state. Results concerning ethosomes showed that for the optimum delivery of the drug to the skin, the drug should be assimilated within the ethosomal vesicles. Ethosomes did not have the ability to improve the delivery of non-confined ketotifen to the skin [46].

3.4 Herpex Simplex Infection

Jain and coworkers developed elastic liposomal formulation containing acyclovir sodium for its improved transdermal delivery by utilizing rotary evaporation method. The formulation was evaluated for shape as well as surface characteristics of the vesicles, size and size distribution, polydispersity index, entrapment efficiency, turbidity, elasticity as well as in vitro drug release. Artificial membranes and rat skin were used for carrying out permeability studies of drug loaded formulation. Confocal Laser Scanning Microscopy (CLSM) was used for assessing the capability of the developed dosage form to penetrate the skin. The results of CLSM revealed that the permeation was enhanced to the cavernous skin layers (up to 160µm) following pathways which were like channels. The authors concluded that the ELs were favorable vehicles for transdermal delivery of acyclovir sodium [27].

3.5 Gout

Singh and coworkers formulated a cyclodextrine-colchicines complex and examined its impact on permeation across skin as well as colchicines deposition in skin. Freeze-drying method was used for preparing the colchicines beta
cyclodextrine (BCD) complex. Nuclear magnetic resonance (NMR) and *in vitro* drug release study were used for confirming the complex formulation. An enhanced transdermal flux (6 fold) was shown by formulation containing cyclodextrin drug complex in comparison to drug solution. The stored effect of transferosomes in skin was determined with the help of skin retention studies. A 12.4 times increase in the amount of drug deposition was observed in case of transferosomes of colchicines complex with cyclodextrin (567±1.5 mg) in comparison to solution of drug (46±1.1 mg). Air pouch model based on induction by monosodium urate was used for assessment of various elastic liposomal dosage forms and solution of drug. In rats, after administration of colchicines-BCD elastic liposomal formulation, superior anti-gout activity with biological effects which persisted for over 24 hours was observed in comparison to drug solution. The biological effects were calculated in terms of volume of exudates, decrease in count of leukocytes, reduction in accumulation of inflammatory cells and deposition of collagen. At the end, the study concluded that colchicines-cyclodextrin- transferosomes exhibited great ability to increase accumulation in skin, enhance release of drug and improvise the site specificity of colchicines [36].

Tiwari and co-workers loaded allopurinol in transfersomes and evaluated their efficacy in the treatment of gout. Thin film hydration process was used for the formulation of transfersomes using soya lecithin, tween 80 and solvent. The results of characterizations done revealed that the formulation was spherical in shape, with a zeta potential and percentage entrapment efficiency of -11.4 mV to -29.6 mV and 52.4-83.87% respectively. Absence of any interaction between the drug and other excipients during formulation of transfersomes was revealed by Fourier Transform Infrared Spectroscopy (FTIR). The cumulative percentage drug release was between 51.87 to 81.87% from the formulations prepared. Further, the optimized drug containing dosage form was transformed into gel and evaluated for pH, rheological behaviour, permeation, irritation as well as *in vitro* studies in rabbit model. The results were better than the standard allopurinol. The authors suggested the prepared transferosomal formulation to be a potential dosage form for the gout treatment [47].

### 3.6 Cutaneous Tuberculosis

Altamimi *and associates* developed isoniazid loaded ELs using phosphatidylcholine (PC) and surfactant having inherent anti-tubercular activity. The formulation was optimized using a full factorial design. The two factors were PC and surfactant which were considered as X1 and X2. The four variables which were dependent were Y1, Y2, Y3 and Y4 which corresponded to size, zeta potential, % entrapment and flux. In order to check and authenticate the mechanism of deposition and penetration of the formulation across the skin of rats, DSC, SEM and CLSM were utilized. In comparison to the formulations containing sodium deoxycholate and span 80, formulation F18 exhibited minimum size of vesicles (~ 78.6 nm) and optimal zeta potential (+ 25.31 mV). OEL (X1 ~ 82.5 mg and X2 ~ 30.5 mg) showed a good correlation between the observed and the predicted values with the maximum desirability (0.943) and absence of any interaction. The spherical shape and the deformability of the vesicles of the OEL were ensured by the morphological and the extrusion studies. All the elastic liposomal formulations exhibited hemocompatibility with a sustained release of the drug. The OEL exhibited enhanced permeation flux which was 1.8, 1.4, 1.8, 1.6 and 8.2 times more than formulations F3, F7, F11, F15, and drug solution, respectively. Reversible perturbation was shown by DSC and SEM whereas penetration into the skin was confirmed by CLSM. Based on the results the authors concluded that the formulated ELs could be a successful approach for controlling cutaneous and systemic tuberculosis [48].

### 3.7 Cancer

Hussain and coworkers prepared ELs loaded with 5-fluorouracil (5-FU) by utilizing different surfactants and aimed to increase permeation of drug through stratum corneum (SC) layer of rat skin. The formulated ELs were evaluated for number and size of vesicles, their entrapment efficiency, turbidity, charge, morphological feature's, *in vitro* drug release, *in vitro* skin permeation as well as *in vivo* hemolytic ability and the results were compared with drug solution. The authors performed CLSM inorder to assess the *in vivo* skin irritation potential of the developed formulation. The elastic liposomal formulations EL3-S60, EL3-S80 and EL3-T80 exhibited drug permeation flux of 77.07 ± 6.34, 89.74 ± 8.5 and 70.90 ± 9.6 mg/cm2 /h respectively in comparison to drug solution (8.958 ± 6.9 mg/cm2 /h) and liposome (36.80 ± 6.4 mg/cm2 /h). A three fold higher drug deposition was shown by the optimized formulation EL3-S80 in comparison to the
solution of drug. From the results of skin irritation and CLSM studies, it was proposed that the optimized gel was incapable of causing skin irritation and had ability of delivering 5-FU into the epidermis for increased topical delivery as compared to solution of drug. Minimum hemolysis was noticed in the case of optimized formulation during the in vitro study. The in vivo toxicity studies and histopathological evaluations indicated that the transferosome had ability of extracting SC to enhance permeation of drug without bringing about any alteration in the skins general anatomy [7].

3.8 Fungal Infections
Patel and parikh used Rotary Flask Evaporation - Sonication method for the formulation of transfersomes loaded with antifungal agent. The authors used Plackett-Burman Design to identify critical process and formulation parameters which affected the size of the vesicles. The authors concluded that lipid as well as surfactant amount, ethanol volume, hydration media and time of hydration had a significant effect on the size of the vesicles [49].

3.9 Wound Healing
Allaw and coworkers utilized the combined effect of glycerol (moisturizing ability), propylene glycol (enhanced permeation ability) and mucin (bioadhesive capability) to improve both the efficacy of transfersomes as well as the efficacy of the drug mangiferin in the skin lesion treatment. The authors formulated mucin modified transfersomes as well as glycoltransfersomes and evaluated their physicochemical properties as well as their efficacy against the treatment of oxidative stress an in vitro and in vivo skin wounds. The results confirmed enhanced deposition of the drug mangiferin in epidermis and dermis besides protection of fibroblasts from oxidative stress. The in vivo studies confirmed the anti-inflammatory efficacy as well as wound healing potential of the glycoltransfersomes [50].

Caddeoa and coworkers used Tween 20, 40, 60 and 80 for the formulation of tocopherol acetate loaded transfersomes. The formulated dosage form exhibited enhanced entrapment efficiency which increased with enhancement in fatty acid chain of Tween from 72% to 90%, small vesicle size of 85nm, were unilamellar and exhibited a polydispersity index of ≤0.27, which was low. The Turbiscan™ technology used for assessing the stability of the formulation indicated that the formulation was stable. The authors concluded that the vesicular carriers formulated were biocompatible with fibroblasts as well as keratinocytes and delivered the encapsulated drug efficiently to the skin. Protection to skin cells against hydrogen peroxide induced oxidative damage was observed when drug loaded transfersomes were used. The authors reported speedy closure of skin wound after the application of formulation. This was attributed by authors to the promotion of cell proliferation as well as migration by transfersomes. The authors confirmed the wound healing potential of transfersomes [51].

3.10 Ocular Diseases
González-Rodríguez and co workers optimized the timolol loaded transferosome formulation by utilizing Taguchi orthogonal experimental design and evaluated its efficacy in open angle glaucoma. The authors asserted that the ratios of lipid to surfactant as well as the surfactant type were the key variables which determined the bilayer flexibility of transfersomes. Based on the results of the study, the authors confirmed that the formulated transfersomes had the potential to enhance the bioavailability of the drug [52].

3.11 Dental Applications
Bryan and coworkers designed and developed a transferosome formulation loaded with local anaesthetic (LA) for the treatment of buccal as well as dental pain. The formulation was developed with the aim to decrease the administration frequency and increase the safety of the administered LA by providing a local effect. A Taguchi design of experiment (DOE) was used to optimize the parameters. Size of the vesicles, polydispersity index (PDI), entrapment efficiency (EE) and charge were the parameters evaluated. The authors reported that the ELs exhibited a size less than 200nm and had a low PDI. The formulation which exhibited less size of vesicles with higher %EE was chosen for in vitro study, the results of which revealed a sustained release of the LA from the formulation over a period of 72 hours [53].

Table 2 gives the applications of ELs in treatment of various diseases.

3.12 Patented Formulations
The advantages associated with ELs have also led to grant of patents. The patented formulations of ELs are given in Table 3.
### Table 2. Applications of ELs in treatment of diseases

| S. No. | Drug | Components | Method of preparation | Disease targeted | Outcome | Reference |
|--------|------|------------|-----------------------|-----------------|---------|-----------|
| 1      | Cetirizine Dihydrochloride | Phospholipon 90G, Edge activators (Span 80, Tween 80, sodium deoxycholate), charge inducer (stearylamine) | Rotary evaporation method | Atopic dermatitis | Reduction in itching score, reduction in dermal eosinophil count and erythema score | [35] |
| 2      | Nifedipine | Soya phosphatidylcholine, edge activator (span 80) | Rotary evaporation method | Hypertension | Enhanced skin permeation, prolonged drug release, and improved site-specificity of nifedipine | [44] |
| 3      | Cyclodextrin-Colchicine Complexes | Soya phosphatidylcholine, Edge activators (Span 60, span 8- and cholesterol) | Conventional rotary evaporation sonication method | Gout | Sustained biological effect, reduction in leukocyte count, decrease in inflammatory cell accumulation | [36] |
| 4      | Isoniazid | Phospholipon 90H, Edge activators (Twee 80, span 80, sodium cholate and sodium deoxycholate) | Rotary evaporation method | Tuberculosis | Enhanced permeation | [48] |
| 5      | 5-fluorouracil | Soya phosphatidylcholine, Edge activator (Span-60, Span-80 and Tween-80) | Conventional rotary evaporation sonication method | Cancer | Improved drug permeation without changing anatomy of skin, minimum haemolysis | [7] |
| 6      | Ketotifen | Lipoid S100, Edge activator (Twee 80) | Conventional mechanical dispersion method | Antihistaminic activity | Improved skin permeation | [46] |
| 7      | Acyclovir Sodium | Soya phosphatidylcholine, Edge activators (Span 40, span 60, span 80) | Rotary evaporation method | Infections such as herpes, chicken pox, etc. | Increased concentration of acyclovir Sodium in plasma in comparison to conventional liposomes | [27] |
| 8      | Clotrimazole | Soya phosphatidylcholine, Edge activators (Span 80, Cholesterol) | Rotary evaporation method | Fungal infections | Enhanced skin permeation and enhanced anti-fungal activity | [26] |
| 9      | Naringenin | Epikuron-200, Edge activators (cholesterol, Tween 80) | Rotary evaporation method | Anti-oxidant activity | Increased deposition of naringenin in skin, | [54] |
| 10     | Curcumin | Phosphatidylcholine, Edge activators (Sodium deoxycholate, Polysorbate 80, Stearylamine) | Film hydration method | Wound healing | Sustained skin penetration of curcumin | [55] |
| 11     | Acetazolamide | Phosphatidylcholine (PC), Edge activators (Twee 80, Span 80, and | Ethanol injection method | Glaucoma | Prolonged drug release, improved ex vivo permeation | [56] |
| S. No. | Drug                                      | Components                                      | Method of preparation | Disease targeted          | Outcome                                                                 | Reference |
|-------|-------------------------------------------|------------------------------------------------|-----------------------|---------------------------|-------------------------------------------------------------------------|-----------|
| 12    | Propranolol hydrochloride                  | Cremophor RH 40, Phosphatidylcholine, Edge activators (Span 40, Span 60 and span 80) | Conventional rotary evaporation sonication method | Anti- Hypertensive         | Enhanced permeation                                                      | [40]      |
| 13    | Rifampicin                                | Phospholipon 90G, edge activator (Tween 80)     | Rotary evaporation method | Anti- tubercular          | Improved bioavailability of rifampicin, sustained and prolonged delivery of rifampicin | [30]      |
| 14    | Aceclofenac                               | Phospholipon 90G, Phospholipon 90H, Edge activator (stearylamine) | Thin film hydration method | Anti- inflammatory        | Safety of aceclofenac delivery was enhanced for topical route             | [39]      |
| 15    | Ammonium glycyrrhizate                    | Phospholipon 90G, Edge activator (Sodium cholate) | Thin layer evaporation method | Anti- inflammatory        | Decreased skin inflammation                                              | [41]      |
| 16    | Lornoxicam                                | Phosphatidylcholine, Edge activators (Sodium deoxycholte, tween 80) | Thin film hydration method | NSAIDs                    | Enhanced permeation                                                      | [42]      |
| 17    | Sulfonaphane                              | Phospholipon 90G, Edge activator (Sodium cholate) | Rotary evaporation method | Against skin cancer       | Enhanced percutaneous permeation of sulfonaphane, improved anti-cancer activity | [57]      |
| 18    | 4-OH Tamoxifen                            | Soya phosphatidylcholine, Emu oil, sodium taurocholate | Thin film hydration method | Against Breast cancer     | Reduction in adverse effects of 4-OH Tamoxifen                          | [58]      |
| 19    | Carvedilol                                | Phospholipids (HEPC, SPC, DSPC), Edge activators (tween 80, sodium cholate) | Thin film hydration method | Against skin cancer       | Suppressed ultraviolet-induced DNA damage, inflammatory gene expression, and apoptosis | [59]      |
| 20    | Ivabradine Hydrochloride                   | Soya lecithin, edge activators (TWEEN 80, Sodium Lauryl Sulphate or Celtrimide) | Ethanol injection method | Against stable angina pectoris | Improved permeability and skin retention of Ivabradine Hydrochloride   | [60]      |
| 21    | Pravastatin sodium and Naringenin         | Omega 3 phospholipid, edge activator (Sodium deoxycholate) | Thin film hydration method | Anti hyperlipidemic       | Synergistic effect of naringenin with omega-3-phospholipids, reversal of hepatic marker enzymes and lipid peroxidative markers induced by pravastatin | [61]      |
| 22    | Paclitaxel                                | Lactose monohydrate, microcrystalline cellulose, Starch, span 20, span 80 and Tween 80 | Rotary evaporation method | Anti cancer               | Paclitaxel loaded protransferosome formulations were found to be toxic for cancer cells where as safe for normal lung fibroblast cells | [62]      |
| S. No. | Drug          | Components                                                                 | Method of preparation         | Disease targeted | Outcome                                                                 | Reference |
|--------|---------------|----------------------------------------------------------------------------|------------------------------|-----------------|-------------------------------------------------------------------------|-----------|
| 23     | Voriconazole  | Phosphatidyl choline from egg yolk, Brij S100                              | Ethanol injection method     | Anti fungal     | Against Candida albicans, voriconazole loaded elastic liposomes showed superior results to voriconazole suspension, with greater and more durable growth inhibition | [63]      |
| 24     | Allopurinol   | Soya lecithin, Edge activator (Tween 80)                                  | Thin-film hydration          | Gout            | Reduced skin irritation, improved in vivo results in comparison to standard allopurinol | [41]      |
| 25     | Carnosine     | Egg phosphatidylcholine (eggPC), Edge activator (Tween 80)                 | Extrusion method             | Ischemic stroke | Reduced infarct volume in ischemia rat models                            | [64]      |

Table 3. Patented formulations of elastic liposomes

| S. No | Patent no  | Patent title                                                                 | Phytotherapeutic used       | Route of application | Summary of invention                                                                 | Reference |
|-------|------------|------------------------------------------------------------------------------|-----------------------------|----------------------|-------------------------------------------------------------------------------------|-----------|
| 1     | EP 2 431 023 A1 | Flexible liposomes of resveratrol and preparation method thereof             | Resveratrol                 | Transdermal          | Thin film hydration method was used for the formulation of flexible liposomes loaded with Resveratol. Resveratol (in the range 0.1 and 10% w/w of liposomes), phospholipids (0.5 and 10%) as well as softener were used for the formulation of ELs. A significant enhancement in the transdermal absorption of drug was observed after its administration as ELs. | [65]      |
| 2     | GB 2 398 495 | A drug preparation comprising at least one anti-tumour drug and a topical carrier for the drug | Bleomycin                   | Topical              | Extrusion method was used for the formulation of ELs. Loaded with bleomycin. The outcomes of the patent revealed that the formulation exhibited improved permeation of the entrapped drug due to the elasticity offered by the ELs. | [66]      |
3.13 Future Perspective

ELs have been exploited extensively by researchers for enhancing the solubility, permeation and bioavailability with a reduction in side effects of many drugs used in the treatment of plethora of diseases. However, the commercialization of these products is still limited, due to their limited scale up by pharmaceutical industries. Besides this, there is scarcity of safety data pertaining to the clinical studies conducted using these vesicular carriers, which further limits their commercialization. Researchers should work towards establishing the cost/benefit ratio of using these vesicular carriers for delivery of drugs along with collecting information related to their safety which would contribute extensively to improving the commercialization as well as customer acceptance of these carriers. Besides this, optional ingredients added to the formulation to impart enhanced elasticity and stability need to be explored more for further improving the performance of these vesicular carriers.

4. CONCLUSION

ELs have been utilized for improving not only the physicochemical properties of the entrapped drugs but have also contributed in providing improvement in pharmacokinetic as well pharmacodynamic properties of drugs both in animal as well as in humans. They have been extensively investigated for the treatment of numerous diseases. However, there is a need for the collaboration of researchers and pharmaceutical industries to improve their commercial viability.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Bhowmik D, Gopinath H, Kumar BP, Duravel S, Kumar KPS. Topical drug delivery system. The Pharma Innovation. 2013;1(9):12-31.
2. Singh S, Vardhan H, Kotla NG, Maddiboyna B, Sharma D, Webster TJ. The role of surfactants in the formulation of elastic liposomal gels containing a synthetic opioid analgesic. Int J Nanomed. 2016;11:1475–82.
3. Sinico C, Fadda AM. Vesicular carriers for dermal drug delivery. Expert Opin Drug Deliv. 2009; 6(8):813–25.
4. Benson HA. Transfersomes for transdermal drug delivery. Expert Opin Drug Deliv. 2006; 3(6):727–37.
5. El Maghraby GM, Barry BW, Williams AC. Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci. 2008;34(4–5):203–22.
6. Benson HAE. Els for topical and transdermal drug delivery. Curr. Drug Deliv. 2009;6:217-26.
7. Hussain A, Samad A, Ramzan M, Ahsan MN, Ur Rehman Z, Ahmad FJ. Elastic liposome-based gel for topical delivery of 5-fluorouracil: in vitro and in vivo investigation. Drug Deliv. 2016;23(4):1115–29.
8. Hussain A, Singh S, Sharma D, Webster TJ, Shafaat K, Faruk A.(2017) Els as novel carriers: recent advances in drug delivery. Int. J. Nanomed. 2017;12:5087-5108.
9. El-Zaafarany GM, Awad GA, Holayel SM, Mortada ND. Role of edge activators and surface charge in developing ultradeformable vesicles with enhanced skin delivery. Int J Pharm. 2010; 397(1–2):164–172.
10. El Maghraby GM, Williams AC, Barry BW. Skin delivery of oestradiol from lipid vesicles: importance of liposome structure. Int J Pharm. 2000;204(1–2):159–169.
11. El Maghraby GM, Williams AC, Barry BW. Interactions of surfactants (edge activators) and skin penetration enhancers with liposomes. Int J Pharm. 2004;276(1–2):143–161.
12. Aggarwal N, Goindi S. Preparation and evaluation of antifungal efficacy of griseofulvin loaded deformable membrane vesicles in optimized guinea pig model of Microsporum canis – dermatophytosis. Int J Pharm. 2012;437(1–2):277–287.
13. López O, Cócera M, Wehrli E, Parra JL, de la Maza A. Solubilization of liposomes by sodium dodecyl sulfate: new mechanism based on the direct formation of mixed
micelles. Arch Biochem Biophys. 1999; 367(2):153–160.

14. Jain S, Jain P, Umamaheswari RB, Jain NK. Transfersomes – a novel vesicular carrier for enhanced transdermal delivery: development, characterization, and performance evaluation. Drug Dev Ind Pharm. 2003;29(9):1013–26.

15. Mishra D, Mishra PK, Dubey V, Dabadghao S, Jain NK. Evaluation of uptake and generation of immune response by murine dendritic cells pulsed with hepatitis B surface antigen-loaded Els. Vaccine. 2007;25(39-40):6939–44.

16. Simões SI, Tapadas JM, Marques CM, Cruz ME, Martins MB, Cevc G. Permeabilisation and solubilisation of soybean phosphatidylcholine bilayer vesicles, as membrane models, by polysorbate, Tween 80. Eur J Pharm Sci. 2005;26(3–4):307–17.

17. Chen J, Lu WL, Gu W, Lu SS, Chen ZP, Cai BC. Skin permeation behavior of Els: role of formulation ingredients. Expert Opin Drug Deliv. 2013;10(6):845–56.

18. Balaguer-Fernández C, Femenia-Font A, Merino V, et al. Elastic vesicles of sumatriptan succinate for transdermal administration: characterization and in vitro permeation studies. J Liposome Res. 2011;21(1):55–59.

19. Ita KB, Du Preez J, Lane ME, Hadgraft J, du Plessis J. Dermal delivery of selected hydrophilic drugs from Els: effect of phospholipid formulation and surfactants. J Pharm Pharmacol. 2007; 59(9):1215–22.

20. Montanari J, Roncaglia DI, Lado LA, Morilla MJ, Romero EL. Avoiding failed reconstitution of ultradeformable liposomes upon dehydration. Int J Pharm. 2009; 372(1–2):184–190.

21. Cevc G, Mazgareanu S, Rother M, Viel U. Occlusion effect on transcutaneous NSAID delivery from conventional and carrier-based formulations. Int J Pharm. 2008;359(1–2):190–97.

22. Cevc G, Schatzlein A, Blume G. Transdermal drug carriers: basic properties, optimization and transfer-efficiency in the case of epicutaneously applied peptides. J Contr. Rel. 1995;36:3–16.

23. El Maghraby GM, Williams AC, Barry BW. Skin delivery of 5-Fluorouracil from ultra deformable and traditional liposomes in vitro. J Pharm Pharmacol. 2001;53:1069–76.

24. Chatzinikoli L, Pippa N, Demetzos C. Preparation and physiochemical characterization of Els: A road-map library for their design. Journal of liposome research. 2019;

25. Nwobodo N, Amin AF, John DE, Abraham U. Formulation and Evaluation of Els of Decitabine prepared by Rotary Evaporation Method. Univers J of Pharm Res. 2019;4(7):1-5.

26. Kumar R, Rana AC, Bala R, Seth N. Formulition and Evaluation of Els of clotrimazole. Int J Drug Dev and Res. 2012;4(3):348-55.

27. Jain SK, Gupta Y, Jain A, Rai K. Enhanced Transdermal delivery of acyclovir Sodium via Els”, Drug Deliv. 2008;15(3):141-47.

28. Vanden Bergh BAI, Wertz PW, Junginger HE, Bouwstra JA. Elasticity of vesicles assessed by electron spin resonance, electron microscopy, and extrusion measurement. Int. J. Pharm. 2001; 217:13–24.

29. Hussain A, Haque MW, Singh SK, Ahmed FJ. Optimized Permeation enhancer for topical delivery of 5-Fluorouracil loaded elastic liposome using design expert: part II. Drug Deliv. 2015; 23(4):1242-53.

30. Hussain A, Altamimi MA, Alsheri S, Imam SS, Singh SK. Vesicular Els for transdermal delivery of rifampicin: in vitro, in vivo and in silico GastroPlus™ prediction studies. Eur J Pharm Sci. 2020;151: 1-18.

31. Contreras MD, Sanchez R. Application of a factorial design to the study of the flow behaviour, spreadability and transparency of a carbopol ETD 2020 gel II. Int J of Pharm. 2002;234:149-57.

32. Singh HP, Tiwary AK, Jain S. Preparation and in vitro, in vivo characterization of Els encapsulating cyclodextrin- colchicine complexes for topical delivery of colchicines. Yakugaku zasshi journal of the Pharmaceutical Society of Japan. 2010;130(3):397-407.

33. Barry BW. Theory of skin permeation enhancement. J control release 199;15:237- 48.

34. Dubey V, Mishra D, Asthana A, Jain NK. Transdermal delivery of a pineal hormone: melatonin via Els. Biomaterials. 2006;27:3491-96.

35. Goindi S, Kumar G, Kumar N, Kaur A. Development of Novel Elastic Vesicle-
Based Topical Formulation of Cetrizine Dihydrochloride for treatment of Atopic Dermatitis. AAPS Pharm. Sci. Tech. 2013;14(4):1284-93.

36. Singh HP, Tiwary AK, Jain S. Preparation and in Vitro, in Vivo Characterization of Els Encapsulating Cyclodextrin-Colchicine Complexes for Topical Delivery of Colchicine. Yakugaku Zasshi. 2010;130(3):397-407.

37. Dar MJ, Khalid S, Varikuti S, Satokar A.R. Nano-elastic liposomes as multdrug carrier of sodium stibogluconate and ketoconazole: A potential new approach for the topical treatment of cutaneous Leishmaniasis. European Journal of Pharmaceutical sciences. 2020;145:1-11.

38. Taha EI, El-Anazi MH, El-Bagory IM, Bayomi MA. Design of liposomal colloidal systems for ocular delivery of ciprofloxacin. Saudi Pharmaceutical Journal. 2014;22:231-239.

39. Sharma G, Goyal H, Thakur K, Raza K, Katare OP. Novel elastic membrane vesicles (EMVs) and ethosomes-mediated effective topical delivery of aceclofenac: a new therapeutic approach for pain and inflammation. Drug Deliv. 2016;23(8):3135-45.

40. Mishra D, Garg M, Vaibhav D, Jain S, Jain NK. Els mediated transdermal delivery of an anti hypertensive agent: propranolol hydrochloride. J pharm sci 2007;98:145-155.

41. Barone A, Cristiano MC, Cilurzo F, Locatelli M, Iannotta D, Marzio LD, Celia C, Paolino D. Ammonium glycyrrhiziate skin delivery from ultradisperse liposomes: a novel use as an anti-inflammatory agent in topical drug delivery. Colloids and Surfaces B. 2020;20:20.

42. Tawfeek HM, Abdellatif AAH, Aleema JAA, Hassan Y A, Faholla D. Transfersomal gel nanocarriers for enhancement of the permeation ofloxazolin. J Drug Deliv Sci and Tech. 2020;56:1-10.

43. Lei W, Yu C, Lin H, Zhou X. Development of tacrolimus-loaded transfersomes for deeper skin penetration enhancement and therapeutic effect improvement in vivo. Asian J Pharm sci. 2013; 8(6):336-45.

44. Aujla M, Rana AC, Seth N, Bala R. Elastic Liposome Mediated Transdermal Delivery of an Anti-Hypertensive agent: Nifedipine. J Drug Deliv and Ther. 2012;2(5):55-60

45. Ahad A, Al-Saleh AA, Al-Mohizea AM, Al-Jenoobi FI, Raish M, Yassin AEB, Alam MA. Formulation and Characterization of novel soft nanovesicles for enhanced transdermal delivery of eprosartan mesylate. Saudi Pharm J. 2017;25(7): 1040-46.

46. Elsayed MMA, Abdallah OY, Naggar VF, Khalafallah NM. Deformable liposomes and ethosomes: Mechanism of enhanced skin delivery. Int J Pharm 2006;322:60–66.

47. Tiwari R, Tiwari G, Singh R. Allopurinol Loaded Transfersomes for the Alleviation of Symptomatic After-effects of Gout: An Account of Pharmaceutical Implications. Curr Drug Ther. 2020;15:1-16.

48. Altamimi MA, Hussain A, Imam SS, Alshehri S, Singh SK, Webster TJ. Transdermal delivery of isoniazid loaded elastic liposomes to control cutaneous and systemic tuberculosis. J Drug Deliv Sci and Tech. 2020;20.

49. Patel BR, Parikh RH. Preparation and formulation of transfersomes containing an antifungal agent for transdermal delivery: Application of Plackett-Burman design to identify significant factors influencing vesicle size. J Pharm Bioall Sci. 2012;4, SupplS1:60-1.

50. Al-law M, Plequezuelos-Villa M, Manca ML, Caddeo C, Aroffu M, Nacher A et al. Innovative strategies to treat skin wounds with mangiferin: fabrication of transfersomes modified with glycols and mucin. Nanomed.15(17).

51. Caddeo C, Manca ML, Peris JE, Usach I, Diez-Salesb O, Matos M et al. Tocopherol-loaded transfersomes: In vitro antioxidant activity and efficacy in skin regeneration. Int J Pharm. 2018; 551(1-2).

52. González-Rodríguez ML, Arroyo CM, Cózar-Bernal MJ, González-R PL, León JM, Calle M et al. Deformability properties of timolol-loaded transfersomes based on the extrusion mechanism. Statistical optimization of the process. Drug Dev Ind Pharm. 2016; 42(10):1683-94.

53. Bryan R, Khan I, Ehteazi T, Saleem I, O’Neill F, Roberts M. Transfersomes as novel carriers for sustained buccal delivery of local anaesthetic J Pharm Drug Deliv Res. 2018;7.

54. Tsai MJ, Huang YB, Fang JW, Fu YS, Wu PC. Preparation and Characterization of Naringenin-Loaded Els for Topical Application. PLoS ONE. 10(7):1-12.

55. Ternullo S, Werning LVS, Holsæter AM, Skalko-Basinet N. Curcumin-In-Deformable Liposomes-In-ChitosanHydrogel as a
Novel Wound Dressing. Pharmaceutics. 2019;12(8):1-14.

56. Mazeyd EA, Abdelaziz AE. Fabrication of Transgelosomes for Enhancing the Ocular Delivery of Acetazolamide: Statistical Optimization, in vitro characterization, and in vivo study. Pharmaceutics. 2020;12(246):1-32.

57. Cristiano MC, Froiio F, Spaccapelo R, Mancuso A, Nistico SP, Udongo BP, et al. Sulforaphane-Loaded Ultradeformable Vesicles as A Potential Natural Nanomedicine for the Treatment of Skin Cancer Diseases. Pharmaceutics. 2019;12(6):1-13.

58. Sundralingam U, Chakravarthi S, Radhakrishnan AK, Muniyandy S, Palanisamy UD. Efficacy of Emu Oil Transfersomes for Local Transdermal Delivery of 4-OH Tamoxifen in the Treatment of Breast Cancer. Pharmaceutics. 2020;12(807):1-18.

59. Chen M, Shamim MdA, Shahid A, Yeung S, Andresen BT, Wang J et al. Topical Delivery of Carvedilol Loaded Nano-Transfersomes for Skin Cancer Chemoprevention. MDPI. 2020; 12(1151): 1-17.

60. Balata GF, Faisal MM, Elghamry HA, Sabry SA. Preparation and Characterization of Ivabradine HCl Transfersomes for Enhanced Transdermal Delivery. J Drug Deliv Sci and Tech. 2020; 20:1-12.

61. Hosnya KM, Alharbia SW, Almehmady AM, Bakhdairda RB, Alkhalidic HM, Sindid AM et al. Preparation and optimization of pravastatin-naringenin nanotransfersomes to enhance bioavailability and reduce hepatic side effects. J Drug Deliv Sci and Tech. 2020;57:1-11.

62. Khan I, Apostolou M, Bnyan R, Houacine C, Elhissi A, Yousaf SS. Paclitaxel-loaded Micro or Nano Transfersome Formulation into Novel Tablets for Pulmonary Drug Delivery via Nebulization. Int J Pharm. 2019;19.

63. Fahmy AM, Hassan M, Setouhy DAE, Tayel SA, Al-Mahallawi MA. Statistical optimization of hyaluronic acid enriched ultradeformable elastosomes for ocular delivery of voriconazole via Box-Behnken design: in vitro characterization and in vivo evaluation. Drug Deliv. 2020;28(1):77-86.

64. Zeb A, Cha JH, Noh AR, Qureshi OS, Kim KW, Choe YH. Neuroprotective effects of carnosine-loaded EIs in cerebral ischemia rat model. J Pharm INVES. 2020;50:373–81

65. Shanghai SQ, Shanghai JR. Flexible liposomes of resveratrol and preparation method thereof. European patent. EP 2 431 023 A1;2012

66. Lau KG, Chopra S. A drug preparation comprising at least one anti-tumour drug and a topical carrier for the drug. UK patent GB 2 398 495;2004

© 2021 Nanda et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sdiarticle4.com/review-history/68915